SCHEMBL2648722

SCHEMBL2648722

Cc1ccc(C=CC(=O)c2ccc(OC(F)(F)F)cc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOB P27338 7/20 0.69
MAOA P21397 4/20 0.69
MAPT P10636 6/20 0.69
CYP1B1 Q16678 4/20 0.68
CYP1A1 P04798 3/20 0.68
RAB9A P51151 2/20 0.61
POLB P06746 1/20 0.61
F3 P13726 2/20 0.59
ALDH1A1 P00352 2/20 0.59
CYP3A4 P08684 1/20 0.59
HPGD P15428 1/20 0.59
CYP2D6 P10635 1/20 0.56
NPC1 O15118 1/20 0.56
LMNA P02545 1/20 0.56
XDH P47989 2/20 0.54
P4HB P07237 1/20 0.54
CALM1 P0DP23 1/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2648725 1.00 MAOB (0.69) MAOBMAOAMAPTCYP1B1CYP1A1
SCHEMBL2665078 1.00 MAOB (0.69) MAOBMAOAMAPTCYP1B1CYP1A1
SCHEMBL2647392 0.93 CYP2D6 (0.63) MAOBMAOAMAPTCYP1B1CYP1A1
SCHEMBL2646833 0.89 F3 (0.77) MAOBMAOAMAPTCYP1B1CYP1A1
SCHEMBL2646835 0.89 F3 (0.77) MAOBMAOAMAPTCYP1B1CYP1A1
SCHEMBL2665209 0.89 F3 (0.77) MAOBMAOAMAPTCYP1B1CYP1A1
SCHEMBL25202905 0.87 XDH (0.67) MAOBMAOAMAPTCYP1B1CYP1A1
SCHEMBL25212966 0.87 F3 (0.68) MAOBMAOAMAPTCYP1B1CYP1A1
SCHEMBL25196548 0.87 XDH (0.67) MAOBMAOAMAPTCYP1B1CYP1A1
SCHEMBL25216348 0.87 F3 (0.68) MAOBMAOAMAPTCYP1B1CYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1463715-A1 NOVEL GLUCAGON ANTAGONISTS NOVO NORDISK A/S (DK) 2004-10-06 EP disclosed
US-6762318-B2 CARBOXYLIC ACID OR TETRAZOLE DERIVATIZED SECONDARY AMIDES; ORAL ADMINISTRATION NOVO NORDISK A/S (DK) 2004-07-13 US disclosed
US-20030236292-A1 Stimulant releasing glucose from liver cells; antidiabetic agents PFIZER INC 2003-12-25 US disclosed
WO-2003048109-A1 NOVEL GLUCAGON ANTAGONISTS NOVO NORDISK A/S (DK) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236292-A1 Stimulant releasing glucose from liver cells; antidiabetic agents GPR119, GLP1R, GIPR MAOB 3317/4885MAOA 3550/4885MAPT 4668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.